Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Equity Average (2016 - 2026)

Champions Oncology has reported Equity Average over the past 16 years, most recently at $4.3 million for Q1 2026.

  • Quarterly results put Equity Average at $4.3 million for Q1 2026, up 38.44% from a year ago — trailing twelve months through Jan 2026 was $4.3 million (up 38.44% YoY), and the annual figure for FY2025 was $934500.0, down 31.61%.
  • Equity Average for Q1 2026 was $4.3 million at Champions Oncology, up from $3.9 million in the prior quarter.
  • Over the last five years, Equity Average for CSBR hit a ceiling of $9.2 million in Q2 2022 and a floor of -$2.0 million in Q2 2024.
  • Median Equity Average over the past 5 years was $3.9 million (2025), compared with a mean of $4.1 million.
  • Biggest five-year swings in Equity Average: plummeted 134.18% in 2024 and later surged 2126.07% in 2025.
  • Champions Oncology's Equity Average stood at $9.1 million in 2022, then tumbled by 89.01% to $998000.0 in 2023, then tumbled by 82.52% to $174500.0 in 2024, then surged by 2126.07% to $3.9 million in 2025, then rose by 9.59% to $4.3 million in 2026.
  • The last three reported values for Equity Average were $4.3 million (Q1 2026), $3.9 million (Q4 2025), and $3.7 million (Q3 2025) per Business Quant data.